JOURNAL ARTICLE

Banks and Private Credit Pitch CVC for Recordati Buyout Debt.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Brown, Silas; Ruckin, Claire 3 of 3

Abstract

The article focuses on the financing efforts behind CVC Capital Partners' proposed acquisition of Italian pharmaceutical company Recordati SpA. Banks and private credit lenders are considering an €8 billion ($9.4 billion) debt package, including senior and junior debt instruments, to support the buyout, which values Recordati at about €10.9 billion. CVC currently owns approximately 47% of Recordati and has engaged potential co-investors for the transaction, which remains subject to due diligence and financing conditions. Founded in 1926, Recordati is a publicly-listed drugmaker known for products like Zanidip and Eligard, with operations spanning specialty care, consumer health, and rare diseases. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/04, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2026
  • Accession Number:193099167
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.